Strata Skin Sciences Stock News

Here's a roundup of top developments in the biotech space over the last 24 hours: Stocks In Focus BioAtla, Bristol-Myers Squibb Announce Collaboration To Evaluate ADC-Opdivo Combo In Solid Tumors BioA

STRATA Skin Sciences Inc (NASDAQ: SSKN ) expects Q4 FY21 sales of $8.8 million - $9.2 million , compared to $6.7 million in Q4 FY20 and the consensus of $8.19 million. For FY21, it expects sales of $29.7 million - $30.1 million (compared to a consensus of $29.11 million), up from $23.1 million in FY20. Cash and cash equivalents, including Full story available on Benzinga.com

STRATA Skin Sciences Inc (NASDAQ: SSKN) expects Q4 FY21 sales of $8.8 million - $9.2 million, compared to $6.7 million in Q4 FY20 and the consensus of $8.19 million. For FY21, it expects sales of $2

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Jan. 10, 2022 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Dec. 27, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for t

TheStreet downgraded shares of STRATA Skin Sciences (NASDAQ:SSKN) from a c- rating to a d rating in a research note issued to investors on Thursday, TheStreetRatingsTable reports. Separately, Zacks Investment Research raised shares of STRATA Skin Sciences from a sell rating to a hold rating in a report on Wednesday, August 18th. Shares of SSKN [] The post STRATA Skin Sciences (NASDAQ:SSKN) Downgraded to D at TheStreet appeared first on ETF Daily News .

HORSHAM, Pa., Dec. 09, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for

HORSHAM, Pa., Dec. 09, 2021 (GLOBE NEWSWIRE) -- STRATA Skin Sciences, Inc. (NASDAQ: SSKN), a medical technology company dedicated to developing, commercializing and marketing innovative products for the treatment of dermatologic conditions, announced that Douglas Strang was appointed to the Board of Directors, effective October 27, 2021. Mr. Strang will assume the role of Audit Committee Chair upon the departure of LuAnn Via, who will step down from the Board on December 31, 2021 as part of a planned transition.

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) was the target of a significant decline in short interest in October. As of October 29th, there was short interest totalling 19,800 shares, a decline of 33.3% from the October 14th total of 29,700 shares. Based on an average daily trading volume, of 70,200 shares, the days-to-cover ratio is presently []

Renaissance Technologies LLC reduced its position in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) by 3.8% during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 1,305,477 shares of the medical device company’s stock after selling 51,100 shares during the quarter. Renaissance Technologies LLC […]

Renaissance Technologies LLC decreased its holdings in STRATA Skin Sciences, Inc. (NASDAQ:SSKN) by 3.8% in the 2nd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,305,477 shares of the medical device companys stock after selling 51,100 shares during the quarter. Renaissance Technologies LLC owned 3.86% of []

STRATA Skin Sciences, Inc. (NASDAQ:SSKN) Equities researchers at Oppenheimer lifted their FY2021 earnings estimates for STRATA Skin Sciences in a research note issued to investors on Thursday, November 11th. Oppenheimer analyst S. Kalia now expects that the medical device company will post earnings of ($0.14) per share for the year, up from their prior []

STRATA Skin Sciences, Inc. (SSKN) CEO Robert Moccia on Q3 2021 Results - Earnings Call Transcript